Decrease of Pneumococcal Community-Acquired Pneumonia Hospitalization and Associated Complications in Children after...

Area of Science:

• Public Health
• Infectious Diseases
• Vaccinology

Background:

• Community-acquired pneumonia (CAP) remains a significant public health concern.
• The 13-valent pneumococcal conjugate vaccine (PCV13) was introduced to reduce the burden of pneumococcal diseases.
• The impact of PCV13 on CAP incidence and severity requires comprehensive evaluation.

Purpose of the Study:

• To evaluate the effect of PCV13 implementation on the incidence and severity of pneumococcal CAP (P-CAP) and unspecific CAP (U-CAP).
• To analyze trends in P-CAP hospitalizations and disease severity before and after PCV13 introduction in Taiwan.

Main Methods:

• Utilized interrupted time-series (ITS) analysis on inpatient data from the Taiwan National Health Insurance Database (NHID) from 2005 to 2016.
• Compared incidence trends of P-CAP and U-CAP before and after PCV13 implementation.
• Assessed changes in hospitalization rates, intensive care, severe pneumonia cases, and invasive procedures.

Main Results:

• PCV13 implementation showed a significant decreasing trend in P-CAP hospitalizations across all age groups (children <1, 2-5 years; adults 19-65 years; elderly ≥66 years).
• Hospitalization reductions ranged from 39% to 59% in different age cohorts.
• Significant decreases in intensive care rates, severe pneumonia cases, and invasive procedures were observed in children aged 2-5 years with P-CAP.

Conclusions:

• PCV13 implementation in Taiwan effectively reduced P-CAP incidence across all evaluated age groups.
• PCV13 also attenuated the severity of P-CAP, particularly in young children (aged 2-5 years).
• These findings support the public health benefits of widespread PCV13 vaccination programs.